Skip to content

Multicenter Randomized Controlled Trial for the usefulness of Dual Red Imaging in endoscopic submucosal dissection

Multicenter Randomized Controlled Trial for the usefulness of Dual Red Imaging in endoscopic submucosal dissection - DRI

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000025134
Enrollment
400
Registered
2016-12-04
Start date
2017-09-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

early esophageal cancer, early gastric cancer, colorectal adenoma, early colorectal cancer

Interventions

The endoscopist commenced the ESD using WLI, switched to DRI immediately when bleeding was detected, then switched back to WLI upon obtaining hemostasis (DRI group). The endoscopist underwent ESD usi

Sponsors

Keio University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1.Early esophageal cancer, depth of cancer invasion is EP or LPM. 2.Early gastric cancer, depth of cancer invasion is mucosal layer or submucosal layer1. 3.Colorectal adenoma, en bloc resection is difficult. 4.Early colorectal cancer, depth of cancer invasion is M or SM1. 5.There is no previous treatment for organ to treat. 6.Blood examination Hemoglobin more than 8.0g/dL, platelet less than 100000 /mm3. 7.Age more than 20,less than 80 years old 8.PS, 0 or 1. 9. We get informed consent from a patient.

Exclusion criteria

Exclusion criteria: 1.More than two lesion are going to be treated. 2.A patient with the bleeding tendency. 3.During dialysis. 4.Residual and reccurence lesion.

Design outcomes

Primary

MeasureTime frame
Shortening the time required for hemostasis.

Secondary

MeasureTime frame
Shortening the treatment time Perforation rate

Countries

Japan

Contacts

Public ContactAi Fujimoto

Keio University School of Medicine Division of Research and Development for Minimally Invasive Treatment, Cancer Center

ai-fujimoto@a8.keio.jp03-5363-3437

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026